Finanzen von Polaryx Therapeutics, Inc (PLYX)PLYXPolaryx Therapeutics, Inc

In the context of the broader market, PLYX competes directly with industry leaders such as CIGL and XHLD. With a market capitalization of $104.18M, it holds a significant position in the sector. When comparing efficiency, PLYX's gross margin of N/A stands against CIGL's 26.11% and XHLD's 70.04%. Such benchmarking helps identify whether Polaryx Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

Polaryx has shown significant financial losses, with a net income of -1,380,000 USD in Q2 2026 and a forward P/E ratio of 0, indicating no earnings expected in the near future. The current ratio has improved to 13.53, suggesting better liquidity, but overall financial health remains a concern.